Global Market Report

Antibiotic Resistance Market Report 2019-2029

Along with revenue prediction for the overall world market, there are 3 segmentations of the Antibiotic Resistance market, with forecasts for forecasts for 7 Diseases, 9 Pathologies, and 6 Drug Class, each forecasted at a global and regional level.

SKU: PHA0480 Category: Tags: , , Code: PHA0480Pages: 194
Clear
← Back to category Therapeutic Drugs

Description

Antibiotic Resistance, our new study reveals trends, R&D progress, and predicted revenues
Where is the Antibiotic Resistance market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2029, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead
Our 253-page report provides 34 tables, 176 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antibiotic Resistance market. See how to exploit the opportunities.

Forecasts to 2029 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2029, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are 3 segmentations of the Antibiotic Resistance market, with forecasts for forecasts for 7 Diseases, 9 Pathologies, and 6 Drug Class, each forecasted at a global and regional level.

Global Antibiotic Resistance Market by Disease
• CUTI
• CIAI
• BSI
• CDI
• ABSSSI
• HABP/VABP
• CABP

Global Antibiotic Resistance Market by Pathology
• Acinetobacter Baumannii
• Pseudomonas Aeruginosa
• Staphylococcus Aureus
• E. coli/K. Pneumoniae
• Streptococcus Pneumoniae
• Clostridium difficile
• Enterococcus faecium
• Haemophilus Influenzae

Global Antibiotic Resistance Market by Drug Class
• Oxazolidinones
• Lipoglycopeptides
• Tetracyclines
• Cephalosporins
• Combination Therapies
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 7 regional and 17 leading national markets:

• North America:
• US
• Canada

• Latin America:
• Brazil
• Mexico
• Rest of Latin America

• Western Europe:
• Germany
• The UK
• Italy
• France
• Spain
• Nordic
• Benelux
• Rest of Western Europe

• Eastern Europe:
• Russia
• Poland
• Rest of Eastern Europe

• Asia-Pacific:
• Japan
• China
• India
• Australia & New Zealand
• ASEAN
• Rest of Asia-Pacific

• MEA:
• GCC Countries
• South Africa
• Northern Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Antibiotic Resistance market, with a focus on this segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Russia, Germany and China in particular, will continue to achieve high revenue growth to 2029.

Leading companies and the potential for market growth
Overall world revenue for Antibiotic Resistance will surpass $8.36 billion in 2019, our work calculates. We predict strong revenue growth through to 2029.
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Antibiotic Resistance Market report helps you
In summary, our 253-page report provides you with the following knowledge:

• Revenue forecasts to 2029 for 3 segmentations of the Antibiotic Resistance market, with forecasts for 7 Diseases, 9 Pathologies, and 6 Drug Class each forecasted at a global and regional level , discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2029 for 6 regional and 21 key national markets , See forecasts for the Antibiotic Resistance market in North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, the UK, Italy, France, Nordic Countries, Benelux, China, India, Japan, Australia & New Zealand, ASEAN countries, GCC Countries, South Africa and Northern Africa.

• Stimulates and restrains companies and the market

• Prospects for established firms and those seeking to enter the market , including company profiles for 10 of the major companies involved in the Antibiotic Resistance market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the Antibiotic Resistance Sequencing market and leading companies. You will find data, trends and predictions.

Get our report today the Global Antibiotic Resistance Market Analysis : Revenue Prospects by Disease (CUTI, CIAI, BSI, CDI, ABSSSI, HABP/VABP, CABP), by Pathology (Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, E. coli/K. Pneumoniae, Streptococcus Pneumoniae, Clostridium difficile, Enterococcus faecium, Haemophilus Influenzae), by Drug class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination therapies, Others) and Geography.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain

2. Antibiotic resistance Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Global Antibiotic resistance Market Size and Forecast
2.3. Market Dynamics
2.3.1. Market Drivers
2.3.2. Market Restraints
2.3.3. Market Opportunities
2.3.4. Mergers and Acquisitions
2.3.5. Entry of New Market Players

3. Global Antibiotic resistance Market Analysis and Forecast, By Disease
3.1. Introduction
3.1.1. Global Antibiotic resistance Market, Annual Growth Rate Comparison, By Disease
3.2. Global Antibiotic resistance Market Size and Forecast, By Disease
3.2.1. CUTI
3.2.2. CIAI
3.2.3. BSI
3.2.4. CDI
3.2.5. ABSSSI
3.2.6. HABP/VABP
3.2.7. CABP
3.3. Global Antibiotic resistance Attractiveness Index, By Disease

4. Global Antibiotic resistance Market Analysis and Forecast, By Pathology
4.1. Introduction
4.1.1. Global Antibiotic resistance Market, Annual Growth Rate Comparison, By Pathology
4.1.2. Global Antibiotic resistance Market Share Comparison, By Pathology (2018 & 2029)
4.2. Global Antibiotic resistance Market Size and Forecast, By Pathology
4.2.1. Acinetobacter Baumannii
4.2.2. Pseudomonas Aeruginosa
4.2.3. Staphylococcus Aureus
4.2.4. E. coli/K. Pneumoniae
4.2.5. Streptococcus Pneumoniae
4.2.6. Clostridium difficile
4.2.7. Enterococcus faecium
4.2.8. Haemophilus Influenzae
4.3. Global Antibiotic resistance Attractiveness Index, By Pathology

5. Global Antibiotic resistance Market Analysis and Forecast, By Drug class
5.1. Introduction
5.1.1. Global Antibiotic resistance Market, Annual Growth Rate Comparison, By Drug class
5.1.2. Global Antibiotic resistance Market Share Comparison, By Drug class (2018 & 2029)
5.2. Global Antibiotic resistance Market Size and Forecast, By Drug class
5.2.1. Oxazolidinones
5.2.2. Lipoglycopeptides
5.2.3. Tetracyclines
5.2.4. Cephalosporins
5.2.5. Combination therapies
5.2.6. Others
5.3. Global Antibiotic resistance Attractiveness Index, By Drug class

6. Global Antibiotic resistance Market Analysis and Forecast, By Region
6.1. Introduction
6.1.1. Global Antibiotic resistance Market, Annual Growth Rate Comparison, By Region
6.1.2. Global Antibiotic resistance Market Share Comparison, By Region (2018 & 2029)
6.2. Global Antibiotic resistance Market Size and Forecast, By Region
6.2.1. North America (U.S., Canada)
6.2.2. Latin America (Brazil, Mexico, Rest of Latin America)
6.2.3. Western Europe (UK, France, Germany, Italy, Spain, Nordic, Benelux, RoWE)
6.2.4. Eastern Europe (Russia, Poland, Rest of Eastern Europe)
6.2.5. Asia Pacific (Japan, China, India, ASEAN, Australia, RoAPAC)
6.2.6. MEA (GCC, South Africa, North Africa, RoMEA)
6.3. Global Antibiotic resistance Market Attractiveness Index, By Region

7. North America Antibiotic resistance Market Analysis and Forecast, 2019-2029
7.1. Introduction
7.1.1. North America Antibiotic resistance Market
7.1.2. North America Antibiotic resistance Market, Annual Growth Rate Comparison, By Country
7.2. North America Antibiotic resistance Market Size and Forecast, By Country
7.2.1. The U.S. Antibiotic resistance Market
7.2.2. Canada Antibiotic resistance Market
7.3. North America Antibiotic resistance Market Size and Forecast, By Disease
7.4. North America Antibiotic resistance Market Size and Forecast, By Pathology
7.5. North America Antibiotic resistance Market Size and Forecast, By Drug class
7.6. North America Antibiotic resistance Market Attractiveness Index
7.7. North America Antibiotic resistance Market Attractiveness Index, By Country
7.8. North America Antibiotic resistance Market Attractiveness Index, By Disease
7.9. North America Antibiotic resistance Market Attractiveness Index, By Pathology
7.10. North America Antibiotic resistance Market Attractiveness Index, By Drug class

8. Latin America Antibiotic resistance Market Analysis and Forecast, 2019-2029
8.1. Introduction
8.1.1. Latin America Antibiotic resistance Market
8.1.2. Latin America Antibiotic resistance Market, Annual Growth Rate Comparison, By Country
8.2. Latin America Antibiotic resistance Market Size and Forecast, By Country
8.2.1. Brazil Antibiotic resistance Market
8.2.2. Mexico Antibiotic resistance Market
8.2.3. Rest of Latin America Antibiotic resistance Market
8.3. Latin America Antibiotic resistance Market Size and Forecast, By Disease
8.4. Latin America Antibiotic resistance Market Size and Forecast, By Pathology
8.5. Latin America Antibiotic resistance Market Size and Forecast, By Drug class
8.6. Latin America Antibiotic resistance Market Attractiveness Index
8.7. Latin America Antibiotic resistance Market Attractiveness Index, By Country
8.8. Latin America Antibiotic resistance Market Attractiveness Index, By Disease
8.9. Latin America Antibiotic resistance Market Attractiveness Index, By Pathology
8.10. Latin America Antibiotic resistance Market Attractiveness Index, By Drug class

9. Western Europe Antibiotic resistance Market Analysis and Forecast, 2019-2029
9.1. Introduction
9.1.1. Western Europe Antibiotic resistance Market
9.1.2. Western Europe Antibiotic resistance Market, Annual Growth Rate Comparison, By Country
9.2. Western Europe Antibiotic resistance Market Size and Forecast, By Country
9.2.1. U.K. Antibiotic resistance Market
9.2.2. France Antibiotic resistance Market
9.2.3. Germany Antibiotic resistance Market
9.2.4. Italy Antibiotic resistance Market
9.2.5. Spain Antibiotic resistance Market
9.2.6. Nordic Antibiotic resistance Market
9.2.7. Benelux Antibiotic resistance Market
9.2.8. Rest of Western Europe Antibiotic resistance Market
9.3. Western Europe Antibiotic resistance Market Size and Forecast, By Disease
9.4. Western Europe Antibiotic resistance Market Size and Forecast, By Pathology
9.5. Western Europe Antibiotic resistance Market Size and Forecast, By Drug class
9.6. Western Europe Antibiotic resistance Market Attractiveness Index
9.7. Western Europe Antibiotic resistance Market Attractiveness Index, By Country
9.8. Western Europe Antibiotic resistance Market Attractiveness Index, By Disease
9.9. Western Europe Antibiotic resistance Market Attractiveness Index, By Pathology
9.10. Western Europe Antibiotic resistance Market Attractiveness Index, By Drug class

10. Eastern Europe Antibiotic resistance Market Analysis and Forecast, 2019-2029
10.1. Introduction
10.1.1. Eastern Europe Antibiotic resistance Market
10.1.2. Eastern Europe Antibiotic resistance Market, Annual Growth Rate Comparison, By Country
10.2. Eastern Europe Antibiotic resistance Market Size and Forecast, By Country
10.2.1. Russia Antibiotic resistance Market
10.2.2. Poland Antibiotic resistance Market
10.2.3. Rest of Eastern Europe Antibiotic resistance Market
10.3. Eastern Europe Antibiotic resistance Market Size and Forecast, By Disease
10.4. Eastern Europe Antibiotic resistance Market Size and Forecast, By Pathology
10.5. Eastern Europe Antibiotic resistance Market Size and Forecast, By Drug class
10.6. Eastern Europe Antibiotic resistance Market Attractiveness Index
10.7. Eastern Europe Antibiotic resistance Market Attractiveness Index, By Country
10.8. Eastern Europe Antibiotic resistance Market Attractiveness Index, By Disease
10.9. Eastern Europe Antibiotic resistance Market Attractiveness Index, By Pathology
10.10. Eastern Europe Antibiotic resistance Market Attractiveness Index, By Drug class

11. Asia Pacific Antibiotic resistance Market Analysis and Forecast, 2019-2029
11.1. Introduction
11.1.1. Asia Pacific Antibiotic resistance Market
11.1.2. Asia Pacific Antibiotic resistance Market, Annual Growth Rate Comparison, By Country
11.2. Asia Pacific Antibiotic resistance Market Size and Forecast, By Country
11.2.1. China Antibiotic resistance Market
11.2.2. India Antibiotic resistance Market
11.2.3. Australia Antibiotic resistance Market
11.2.4. ASEAN Antibiotic resistance Market
11.2.5. Japan Antibiotic resistance Market
11.2.6. Rest of Asia Pacific Antibiotic resistance Market
11.3. Asia Pacific Antibiotic resistance Market Size and Forecast, By Disease
11.4. Asia Pacific Antibiotic resistance Market Size and Forecast, By Pathology
11.5. Asia Pacific Antibiotic resistance Market Size and Forecast, By Drug class
11.6. Asia Pacific Antibiotic resistance Market Attractiveness Index
11.7. Asia Pacific Antibiotic resistance Market Attractiveness Index, By Country
11.8. Asia Pacific Antibiotic resistance Market Attractiveness Index, By Disease
11.9. Asia Pacific Antibiotic resistance Market Attractiveness Index, By Pathology
11.10. Asia Pacific Antibiotic resistance Market Attractiveness Index, By Drug class

12. MEA Antibiotic resistance Market Analysis and Forecast, 2019-2029
12.1. Introduction
12.1.1. MEA Antibiotic resistance Market
12.1.2. MEA Antibiotic resistance Market, Annual Growth Rate Comparison, By Country
12.2. MEA Antibiotic resistance Market Size and Forecast, By Country
12.2.1. GCC Antibiotic resistance Market
12.2.2. South Africa Antibiotic resistance Market
12.2.3. North Africa Antibiotic resistance Market
12.2.4. Rest of MEA Antibiotic resistance Market
12.3. MEA Antibiotic resistance Market Size and Forecast, By Disease
12.4. MEA Antibiotic resistance Market Size and Forecast, By Pathology
12.5. MEA Antibiotic resistance Market Size and Forecast, By Drug class
12.6. MEA Antibiotic resistance Market Attractiveness Index
12.7. MEA Antibiotic resistance Market Attractiveness Index, By Country
12.8. MEA Antibiotic resistance Market Attractiveness Index, By Disease
12.9. MEA Antibiotic resistance Market Attractiveness Index, By Pathology
12.10. MEA Antibiotic resistance Market Attractiveness Index, By Drug class

13. Leading Companies in the Antibiotic resistance Market
13.1. Competition Dashboard
13.2. Company Share Analysis
13.3. Company Profiling of 25 Major Players
13.3.1. Company Overview
13.3.2. Disease Offerings
13.3.3. Financial Performance (2016-2018)
13.3.4. Recent Initiatives
13.3.5. Average Gross Margin (2016-2018)

14. Conclusion

15. Glossary

List of Figures
16.1. Research design
16.2. Market segmentation & scope
16.3. Value chain analysis
16.4. Porter's Five Forces
16.5. Market summary
16.6. Market driver analysis (Current & Future Impact)
16.7. Market restraint analysis (Current & Future Impact)
16.8. Global Antibiotic resistance Market by Disease, 2019-2029 (USD million)
16.9. Global Antibiotic resistance Market for CUTI, 2019-2029 (USD million)
16.10. Global Antibiotic resistance Market for CIAI, 2019-2029 (USD million)
16.11. Global Antibiotic resistance Market for BSI, 2019-2029 (USD million)
16.12. Global Antibiotic resistance Market for CDI, 2019-2029 (USD million)
16.13. Global Antibiotic resistance Market for HABP/VABP, 2019-2029 (USD million)
16.14. Global Antibiotic resistance Market for ABSSSI, 2019-2029 (USD million)
16.15. Global Antibiotic resistance Market forCABP, 2019-2029 (USD million)
16.16. Global Antibiotic resistance Market by Pathology, 2019-2029 (USD million)
16.17. Global Antibiotic resistance Market for Acinetobacter Baumannii, 2019 - 2029 (USD million)
16.18. Global Antibiotic resistance Market for Pseudomonas Aeruginosa, 2019 - 2029 (USD million)
16.19. Global Antibiotic resistance Market for Staphylococcus Aureus, 2019 - 2029 (USD million)
16.20. Global Antibiotic resistance Market for E. coli/K. Pneumoniae, 2019 - 2029 (USD million)
16.21. Global Antibiotic resistance Market for Streptococcus Pneumoniae, 2019 - 2029 (USD million)
16.22. Global Antibiotic resistance Market for Clostridium difficile, 2019 - 2029 (USD million)
16.23. Global Antibiotic resistance Market for Enterococcus faecium, 2019 - 2029 (USD million)
16.24. Global Antibiotic resistance Market for Haemophilus Influenzae, 2019 - 2029 (USD million)
16.25. Global Antibiotic resistance Market by Drug class, 2019-2029 (USD million)
16.26. Global Antibiotic resistance Market for Oxazolidinones, 2019-2029 (USD million)
16.27. Global Antibiotic resistance Market for Lipoglycopeptides, 2019-2029 (USD million)
16.28. Global Antibiotic resistance Market for Tetracyclines, 2019 - 2029 (USD million)
16.29. Global Antibiotic resistance Market for Cephalosporins, 2019-2029 (USD million)
16.30. Global Antibiotic resistance Market for Combination therapies, 2019 - 2029 (USD million)
16.31. Global Antibiotic resistance Market for Others, 2019 - 2029 (USD million)
16.32. North America Antibiotic resistance Market by Disease, 2019-2029 (USD million)
16.33. North America Antibiotic resistance Market for CUTI, 2019-2029 (USD million)
16.34. North America Antibiotic resistance Market for CIAI, 2019-2029 (USD million)
16.35. North America Antibiotic resistance Market for BSI, 2019-2029 (USD million)
16.36. North America Antibiotic resistance Market for CDI, 2019-2029 (USD million)
16.37. North America Antibiotic resistance Market for HABP/VABP, 2019-2029 (USD million)
16.38. North America Antibiotic resistance Market for ABSSSI, 2019-2029 (USD million)
16.39. North America Antibiotic resistance Market forCABP, 2019-2029 (USD million)
16.40. North America Antibiotic resistance Market by Pathology, 2019-2029 (USD million)
16.41. North America Antibiotic resistance Market for Acinetobacter Baumannii, 2019 - 2029 (USD million)
16.42. North America Antibiotic resistance Market for Pseudomonas Aeruginosa, 2019 - 2029 (USD million)
16.43. North America Antibiotic resistance Market for Staphylococcus Aureus, 2019 - 2029 (USD million)
16.44. North America Antibiotic resistance Market for E. coli/K. Pneumoniae, 2019 - 2029 (USD million)
16.45. North America Antibiotic resistance Market for Streptococcus Pneumoniae, 2019 - 2029 (USD million)
16.46. North America Antibiotic resistance Market for Clostridium difficile, 2019 - 2029 (USD million)
16.47. North America Antibiotic resistance Market for Enterococcus faecium, 2019 - 2029 (USD million)
16.48. North America Antibiotic resistance Market for Haemophilus Influenzae, 2019 - 2029 (USD million)
16.49. North America Antibiotic resistance Market by Drug class, 2019-2029 (USD million)
16.50. North America Antibiotic resistance Market for Oxazolidinones, 2019-2029 (USD million)
16.51. North America Antibiotic resistance Market for Lipoglycopeptides, 2019-2029 (USD million)
16.52. North America Antibiotic resistance Market for Tetracyclines, 2019 - 2029 (USD million)
16.53. North America Antibiotic resistance Market for Cephalosporins, 2019 - 2029 (USD million)
16.54. North America Antibiotic resistance Market for Combination therapies, 2019 - 2029 (USD million)
16.55. North America Antibiotic resistance Market for Others, 2019 - 2029 (USD million)
16.56. Latin America Antibiotic resistance Market by Disease, 2019-2029 (USD million)
16.57. Latin America Antibiotic resistance Market for CUTI, 2019-2029 (USD million)
16.58. Latin America Antibiotic resistance Market for CIAI, 2019-2029 (USD million)
16.59. Latin America Antibiotic resistance Market for BSI, 2019-2029 (USD million)
16.60. Latin America Antibiotic resistance Market for CDI, 2019-2029 (USD million)
16.61. Latin America Antibiotic resistance Market for HABP/VABP, 2019-2029 (USD million)
16.62. Latin America Antibiotic resistance Market for ABSSSI, 2019-2029 (USD million)
16.63. Latin America Antibiotic resistance Market forCABP, 2019-2029 (USD million)
16.64. Latin America Antibiotic resistance Market by Pathology, 2019-2029 (USD million)
16.65. Latin America Antibiotic resistance Market for Acinetobacter Baumannii, 2019 - 2029 (USD million)
16.66. Latin America Antibiotic resistance Market for Pseudomonas Aeruginosa, 2019 - 2029 (USD million)
16.67. Latin America Antibiotic resistance Market for Staphylococcus Aureus, 2019 - 2029 (USD million)
16.68. Latin America Antibiotic resistance Market for E. coli/K. Pneumoniae, 2019 - 2029 (USD million)
16.69. Latin America Antibiotic resistance Market for Streptococcus Pneumoniae, 2019 - 2029 (USD million)
16.70. Latin America Antibiotic resistance Market for Clostridium difficile, 2019 - 2029 (USD million)
16.71. Latin America Antibiotic resistance Market for Enterococcus faecium, 2019 - 2029 (USD million)
16.72. Latin America Antibiotic resistance Market for Haemophilus Influenzae, 2019 - 2029 (USD million)
16.73. Latin America Antibiotic resistance Market by Drug class, 2019-2029 (USD million)
16.74. Latin America Antibiotic resistance Market for Oxazolidinones, 2019 - 2029 (USD million)
16.75. Latin America Antibiotic resistance Market for Lipoglycopeptides, 2019 - 2029 (USD million)
16.76. Latin America Antibiotic resistance Market for Tetracyclines, 2019 - 2029 (USD million)
16.77. Latin America Antibiotic resistance Market for Cephalosporins, 2019 - 2029 (USD million)
16.78. Latin America Antibiotic resistance Market for Combination therapies, 2019 - 2029 (USD million)
16.79. Latin America Antibiotic resistance Market for Others, 2019 - 2029 (USD million)
16.80. Western Europe Antibiotic resistance Market by Disease, 2019-2029 (USD million)
16.81. Western Europe Antibiotic resistance Market for CUTI, 2019-2029 (USD million)
16.82. Western Europe Antibiotic resistance Market for CIAI, 2019-2029 (USD million)
16.83. Western Europe Antibiotic resistance Market for BSI, 2019-2029 (USD million)
16.84. Western Europe Antibiotic resistance Market for CDI, 2019-2029 (USD million)
16.85. Western Europe Antibiotic resistance Market for HABP/VABP, 2019-2029 (USD million)
16.86. Western Europe Antibiotic resistance Market for ABSSSI, 2019-2029 (USD million)
16.87. Western Europe Antibiotic resistance Market forCABP, 2019-2029 (USD million)
16.88. Western Europe Antibiotic resistance Market by Pathology, 2019-2029 (USD million)
16.89. Western Europe Antibiotic resistance Market for Acinetobacter Baumannii, 2019 - 2029 (USD million)
16.90. Western Europe Antibiotic resistance Market for Pseudomonas Aeruginosa, 2019 - 2029 (USD million)
16.91. Western Europe Antibiotic resistance Market for Staphylococcus Aureus, 2019 - 2029 (USD million)
16.92. Western Europe Antibiotic resistance Market for E. coli/K. Pneumoniae, 2019 - 2029 (USD million)
16.93. Western Europe Antibiotic resistance Market for Streptococcus Pneumoniae, 2019 - 2029 (USD million)
16.94. Western Europe Antibiotic resistance Market for Clostridium difficile, 2019 - 2029 (USD million)
16.95. Western Europe Antibiotic resistance Market for Enterococcus faecium, 2019 - 2029 (USD million)
16.96. Western Europe Antibiotic resistance Market for Haemophilus Influenzae, 2019 - 2029 (USD million)
16.97. Western Europe Antibiotic resistance Market by Drug class, 2019-2029 (USD million)
16.98. Western Europe Antibiotic resistance Market for Oxazolidinones, 2019 - 2029 (USD million)
16.99. Western Europe Antibiotic resistance Market for Lipoglycopeptides, 2019 - 2029 (USD million)
16.100. Western Europe Antibiotic resistance Market for Tetracyclines, 2019 - 2029 (USD million)
16.101. Western Europe Antibiotic resistance Market for Cephalosporins, 2019 - 2029 (USD million)
16.102. Western Europe Antibiotic resistance Market for Combination therapies, 2019 - 2029 (USD million)
16.103. Western Europe Antibiotic resistance Market for Others, 2019 - 2029 (USD million)
16.104. Eastern Europe Antibiotic resistance Market by Disease, 2019-2029 (USD million)
16.105. Eastern Europe Antibiotic resistance Market for CUTI, 2019-2029 (USD million)
16.106. Eastern Europe Antibiotic resistance Market for CIAI, 2019-2029 (USD million)
16.107. Eastern Europe Antibiotic resistance Market for BSI, 2019-2029 (USD million)
16.108. Eastern Europe Antibiotic resistance Market for CDI, 2019-2029 (USD million)
16.109. Eastern Europe Antibiotic resistance Market for HABP/VABP, 2019-2029 (USD million)
16.110. Eastern Europe Antibiotic resistance Market for ABSSSI, 2019-2029 (USD million)
16.111. Eastern Europe Antibiotic resistance Market forCABP, 2019-2029 (USD million)
16.112. Eastern Europe Antibiotic resistance Market by Pathology, 2019-2029 (USD million)
16.113. Eastern Europe Antibiotic resistance Market for Acinetobacter Baumannii, 2019 - 2029 (USD million)
16.114. Eastern Europe Antibiotic resistance Market for Pseudomonas Aeruginosa, 2019 - 2029 (USD million)
16.115. Eastern Europe Antibiotic resistance Market for Staphylococcus Aureus, 2019 - 2029 (USD million)
16.116. Eastern Europe Antibiotic resistance Market for E. coli/K. Pneumoniae, 2019 - 2029 (USD million)
16.117. Eastern Europe Antibiotic resistance Market for Streptococcus Pneumoniae, 2019 - 2029 (USD million)
16.118. Eastern Europe Antibiotic resistance Market for Clostridium difficile, 2019 - 2029 (USD million)
16.119. Eastern Europe Antibiotic resistance Market for Enterococcus faecium, 2019 - 2029 (USD million)
16.120. Eastern Europe Antibiotic resistance Market for Haemophilus Influenzae, 2019 - 2029 (USD million)
16.121. Eastern Europe Antibiotic resistance Market by Drug class, 2019-2029 (USD million)
16.122. Eastern Europe Antibiotic resistance Market for Oxazolidinones, 2019 - 2029 (USD million)
16.123. Eastern Europe Antibiotic resistance Market for Lipoglycopeptides, 2019 - 2029 (USD million)
16.124. Eastern Europe Antibiotic resistance Market for Tetracyclines, 2019 - 2029 (USD million)
16.125. Eastern Europe Antibiotic resistance Market for Cephalosporins, 2019 - 2029 (USD million)
16.126. Eastern Europe Antibiotic resistance Market for Combination therapies, 2019 - 2029 (USD million)
16.127. Eastern Europe Antibiotic resistance Market for Others, 2019 - 2029 (USD million)
16.128. Asia Pacific Antibiotic resistance Market by Disease, 2019-2029 (USD million)
16.129. Asia Pacific Antibiotic resistance Market for CUTI, 2019-2029 (USD million)
16.130. Asia Pacific Antibiotic resistance Market for CIAI, 2019-2029 (USD million)
16.131. Asia Pacific Antibiotic resistance Market for BSI, 2019-2029 (USD million)
16.132. Asia Pacific Antibiotic resistance Market for CDI, 2019-2029 (USD million)
16.133. Asia Pacific Antibiotic resistance Market for HABP/VABP, 2019-2029 (USD million)
16.134. Asia Pacific Antibiotic resistance Market for ABSSSI, 2019-2029 (USD million)
16.135. Asia Pacific Antibiotic resistance Market forCABP, 2019-2029 (USD million)
16.136. Asia Pacific Antibiotic resistance Market by Pathology, 2019-2029 (USD million)
16.137. Asia Pacific Antibiotic resistance Market for Acinetobacter Baumannii, 2019 - 2029 (USD million)
16.138. Asia Pacific Antibiotic resistance Market for Pseudomonas Aeruginosa, 2019 - 2029 (USD million)
16.139. Asia Pacific Antibiotic resistance Market for Staphylococcus Aureus, 2019 - 2029 (USD million)
16.140. Asia Pacific Antibiotic resistance Market for E. coli/K. Pneumoniae, 2019 - 2029 (USD million)
16.141. Asia Pacific Antibiotic resistance Market for Streptococcus Pneumoniae, 2019 - 2029 (USD million)
16.142. Asia Pacific Antibiotic resistance Market for Clostridium difficile, 2019 - 2029 (USD million)
16.143. Asia Pacific Antibiotic resistance Market for Enterococcus faecium, 2019 - 2029 (USD million)
16.144. Asia Pacific Antibiotic resistance Market for Haemophilus Influenzae, 2019 - 2029 (USD million)
16.145. Asia Pacific Antibiotic resistance Market by Drug class, 2019-2029 (USD million)
16.146. Asia Pacific Antibiotic resistance Market for Oxazolidinones, 2019 - 2029 (USD million)
16.147. Asia Pacific Antibiotic resistance Market for Lipoglycopeptides, 2019 - 2029 (USD million)
16.148. Asia Pacific Antibiotic resistance Market for Tetracyclines, 2019 - 2029 (USD million)
16.149. Asia Pacific Antibiotic resistance Market for Cephalosporins, 2019 - 2029 (USD million)
16.150. Asia Pacific Antibiotic resistance Market for Combination therapies, 2019 - 2029 (USD million)
16.151. Asia Pacific Antibiotic resistance Market for Others, 2019 - 2029 (USD million)
16.152. MEA Antibiotic resistance Market by Disease, 2019-2029 (USD million)
16.153. MEA Antibiotic resistance Market for CUTI, 2019-2029 (USD million)
16.154. MEA Antibiotic resistance Market for CIAI, 2019-2029 (USD million)
16.155. MEA Antibiotic resistance Market for BSI, 2019-2029 (USD million)
16.156. MEA Antibiotic resistance Market for CDI, 2019-2029 (USD million)
16.157. MEA Antibiotic resistance Market for HABP/VABP, 2019-2029 (USD million)
16.158. MEA Antibiotic resistance Market for ABSSSI, 2019-2029 (USD million)
16.159. MEA Antibiotic resistance Market forCABP, 2019-2029 (USD million)
16.160. MEA Antibiotic resistance Market by Pathology, 2019-2029 (USD million)
16.161. MEA Antibiotic resistance Market for Acinetobacter Baumannii, 2019 - 2029 (USD million)
16.162. MEA Antibiotic resistance Market for Pseudomonas Aeruginosa, 2019 - 2029 (USD million)
16.163. MEA Antibiotic resistance Market for Staphylococcus Aureus, 2019 - 2029 (USD million)
16.164. MEA Antibiotic resistance Market for E. coli/K. Pneumoniae, 2019 - 2029 (USD million)
16.165. MEA Antibiotic resistance Market for Streptococcus Pneumoniae, 2019 - 2029 (USD million)
16.166. MEA Antibiotic resistance Market for Clostridium difficile, 2019 - 2029 (USD million)
16.167. MEA Antibiotic resistance Market for Enterococcus faecium, 2019 - 2029 (USD million)
16.168. MEA Antibiotic resistance Market for Haemophilus Influenzae, 2019 - 2029 (USD million)
16.169. MEA Antibiotic resistance Market by Drug class, 2019-2029 (USD million)
16.170. MEA Antibiotic resistance Market for Oxazolidinones, 2019 - 2029 (USD million)
16.171. MEA Antibiotic resistance Market for Lipoglycopeptides, 2019 - 2029 (USD million)
16.172. MEA Antibiotic resistance Market for Tetracyclines, 2019 - 2029 (USD million)
16.173. MEA Antibiotic resistance Market for Cephalosporins, 2019 - 2029 (USD million)
16.174. MEA Antibiotic resistance Market for Combination therapies, 2019 - 2029 (USD million)
16.175. MEA Antibiotic resistance Market for Others, 2019 - 2029 (USD million)
16.176. List of Companies

List of Tables
17.1. Global Antibiotic resistance Market, by Disease, 2019-2029 (USD million)
17.2. Global Antibiotic resistance Market, by Pathology, 2019-2029 (USD million)
17.3. Global Antibiotic resistance Market, by Drug class, 2019-2029 (USD million)
17.4. North America Antibiotic resistance Market, 2019-2029 (USD million)
17.5. U.S. Antibiotic resistance Market, 2019-2029 (USD million)
17.6. Canada Antibiotic resistance Market, 2019-2029 (USD million)
17.7. Latin America Antibiotic resistance Market, 2019-2029 (USD million)
17.8. Brazil Antibiotic resistance Market, 2019-2029 (USD million)
17.9. Mexico Antibiotic resistance Market, 2019-2029 (USD million)
17.10. Rest of Latin America Antibiotic resistance Market, 2019-2029 (USD million)
17.11. Western Europe Antibiotic resistance Market, 2019-2029 (USD million)
17.12. UK Antibiotic resistance Market, 2019-2029 (USD million)
17.13. France Antibiotic resistance Market, 2019-2029 (USD million)
17.14. Germany Antibiotic resistance Market, 2019-2029 (USD million)
17.15. Italy Antibiotic resistance Market, 2019-2029 (USD million)
17.16. Nordic Antibiotic resistance Market, 2019-2029 (USD million)
17.17. Benelux Antibiotic resistance Market, 2019-2029 (USD million)
17.18. Rest of Western Europe Antibiotic resistance Market, 2019-2029 (USD million)
17.19. Eastern Europe Antibiotic resistance Market, 2019-2029 (USD million)
17.20. Russia Antibiotic resistance Market, 2019-2029 (USD million)
17.21. Poland Antibiotic resistance Market, 2019-2029 (USD million)
17.22. Rest of Eastern Europe Antibiotic resistance Market, 2019-2029 (USD million)
17.23. Asia Pacific Antibiotic resistance Market, 2019-2029 (USD million)
17.24. Japan Antibiotic resistance Market, 2019-2029 (USD million)
17.25. India Antibiotic resistance Market, 2019-2029 (USD million)
17.26. Australia Antibiotic resistance Market, 2019-2029 (USD million)
17.27. ASEAN Antibiotic resistance Market, 2019-2029 (USD million)
17.28. China Antibiotic resistance Market, 2019-2029 (USD million)
17.29. Rest of Asia Pacific Antibiotic resistance Market, 2019-2029 (USD million)
17.30. MEA Antibiotic resistance Market, 2019-2029 (USD million)
17.31. South Africa Antibiotic resistance Market, 2019-2029 (USD million)
17.32. North Africa Antibiotic resistance Market, 2019-2029 (USD million)
17.33. GCC Antibiotic resistance Market, 2019-2029 (USD million)
17.34. Rest of MEA Antibiotic resistance Market, 2019-2029 (USD million)

Achaogen, Inc.
Allergan
AmpliPhi Biosciences
Basilea Pharmaceutica Ltd.
BioFilm Pharma
Biolytx Pharmaceuticals
BioVersys GmbH
Eligo Bioscience
Entasis Therapeutics
Innovation Pharmaceuticals
Integrated Biotherapeutics
Macrolide Pharmaceuticals
Melinta Therapeutics
Merck
Nabriva Therapeutics
Nemesis Bioscience
NovaBiotics
PARATEK therapeutics
Pfizer
Phage Technologies S.A
SelectX Pharmaceuticals, Inc.
Seres Therapeutics, Inc.
Tetraphase Pharmaceuticals
The Medicines Company
Westway Health
Wockhardt therapeutics